Long-term effectiveness of the combination of iguratimod and alendronate in Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis (SAPHO) syndrome: a prospective cohort study
Authors' conclusion
The combination of IGU and Alendronate as initial treatment may be effective for the long-term management of SAPHO syndrome.
Study context
- Population
- Patients with SAPHO syndrome followed up >2 years, Peking University Third Hospital and Beijing Jishuitan Hospital, 2017–2024
- Participants
- 17 patients
- Outcome
- Long-term effectiveness (overall response to therapy)
Methodological detailstwo-centre, single-arm
- Two-centre
- Single-arm
Main finding
As reported in the abstract
Osteoarticular involvement (17/17): response · median (IQR) follow-up 2.91 (2.34) years
Complete improvement without any recurrence
35.30%
6/17
Partial improvement
11.76%
2/17
Intermittent flares
52.94%
9/17
Observational data: associations, not effects.
Further findings
Skin involvement (11/17): response
- Complete improvement
- 63.64% (7/11)
- Partial improvement
- 27.27% (3/11)
- Intermittent recurrence
- 9.09% (1/11)
Function and symptoms
- Regained complete independence and resumed work
- 88.26% (15/17)
- Alleviation of anxiety and insomnia
- 94.12% (16/17)
Treatment cessation · end of last follow-up
- Ceased treatment
- 52.94% (9/17)
- Mean duration before cessation
- 25.22 months
- Recurrence after cessation
- 22.22% (2/9)
- Mean treatment duration (all)
- 39.10 months
Original publication
Long-term effectiveness of the combination of iguratimod and alendronate in SAPHO syndrome: a prospective cohort study. Rheumatology (Oxford). Published 26 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →